Akarna Therapeutics Ltd. closed a $15 million series B preferred stock financing.
Apellis Pharmaceuticals Inc. raised $47.1 million from a series D financing round.
Corvidia Therapeutics Inc. raised $26 million in a series A financing round.
Karo Bio AB will gross $29.6 million in a discounted share offering on the Nasdaq OMX Nordic market in Stockholm.
Lightstone Ventures closed a $50 million fund, Lightstone Singapore LP, focused on investing in Singapore-based life sciences technologies and companies.
Pliant Therapeutics Inc. raised $45 million from a series A financing.
Proteostasis Therapeutics Inc. closed its IPO of 6.25 million shares of common stock at $8 each for gross proceeds of $50 million.
Scarx Therapeutics Inc. closed a $2 million series A round.
Shield Therapeutics Ltd. generated $47 million in an institutional share placing that accompanies its admission to the Alternative Investment Market of the London Stock Exchange.
Synlogic Inc. closed a series B investment round with $40 million in additional financing.
Aequus Pharmaceuticals Inc. signed a licensing agreement with Supernus Pharmaceuticals Inc. for the Canadian commercial rights to Trokendi XR and Oxtellar XR, which are approved to treat epilepsy.
Agilis Biotherapeutics LLC and Waisman Biomanufacturing formed an exclusive partnership agreement for the production of Agilis' gene therapy product.
Albumedix A/S inked an agreement to combine its albumin-based drug delivery technology, Veltis, with the site-specific maleimide chemistry platform at Thiologics Ltd.
Bind Therapeutics Inc. and Synergy Pharmaceuticals Inc. are collaborating on research to engineer Accurins from Bind that incorporate Synergy's uroguanylin analogues to explore the potential targeting of guanylate cyclase-C receptors expressed on tumors.
Bristol-Myers Squibb Co. and the Dana-Farber Cancer Institute inked a research collaboration as part of the multi-institutional Immuno-Oncology Rare Population Malignancy program.
Caladrius Biosciences Inc. licensed global rights to its cell-derived dermatology topical skin application technology to Aivita Biomedical Inc.
Capsugel and Pulmatrix Inc. formed a collaboration to develop inhaled therapeutics targeting pulmonary diseases.
Gtreebnt Co. Ltd. entered an agreement with the Oklahoma Medical Research Foundation to acquire the rights to OKN-007, a new investigational drug for the treatment of glioblastoma.
Immunocellular Therapeutics Ltd. said it entered an agreement with Stanford University for an option to evaluate an license intellectual property related to the identification of T-cell receptors.
Nanoviricides Inc. entered an agreement with Baylor College of Medicine for the testing of its nanoviricides drug candidates in a small animal model of ocular virus infections.
Philogen SpA and Abbvie Inc. said they entered a second collaboration to discover and develop types of armed antibody products.
. . . And More
Abbvie Inc. joined the Dementia Consortium, a global early stage drug discovery collaboration.
Catalyst Pharmaceuticals Inc. received a refusal to file letter from the FDA for its new drug application for rare disease drug Firdapse (amifampridine phosphate).
Drug Innovation Ventures and the Emory Institute for Drug Development said they initiated a program to discover and develop antivirals for the Zika virus.
Immune Response Biopharma Inc. received a complete response letter from the FDA for its HIV vaccine, Remune HIV-1 Immunogen, for adults.
Genentech Inc., a unit of Roche AG, said the FDA designated Ocrevus (ocrelizumab) a breakthrough therapy to treat primary progressive multiple sclerosis.
Lightlake Therapeutics Inc. changed its corporate name to Opiant Pharmaceuticals Inc. to reflect its historical focus on opioid antagonist treatments.
Marina Biotech Inc. said its board authorized a process to explore strategic alternatives, including the company's sale.
The FDA issued Merck & Co. Inc. a complete response letter to its supplemental new drug applications for cholesterol-lowering drugs Zetia and Vytorin, which sought to add claims that they reduced the risk of cardiovascular events.